Australia will expand its Pharmaceutical Benefits Scheme (PBS) listing for pembrolizumab, sold as Keytruda, on September 1, 2026, adding advanced cholangiocarcinoma, ovarian cancer and Merkel cell carcinoma. The Australian government expects about 700 people a year to benefit and says an unsubsidized prescription might cost A$14,800. At the Reserve Bank of Australia's August 31, 2026, reference rate, that amount is about US$10,600.

The PBS is Australia's government program for subsidizing listed medicines. The change lowers the prescription cost for patients who meet the Australian listing's conditions; it does not make pembrolizumab subsidized for everyone with one of the named cancers.

Three cancer indications enter the expanded listing

Cholangiocarcinoma is bile duct cancer, while Merkel cell carcinoma is a rare skin cancer. The announcement lists ovarian cancer as the third additional indication. It describes the expansion as covering patients with advanced and high-risk cancers but does not publish a separate beneficiary estimate for each cancer.

A separate PBS change adds pembrolizumab in combination with enfortumab vedotin, sold as Padcev, for stage III or IV urothelial cancer. More than 490 Australians a year are expected to benefit, and the government puts the possible unsubsidized price at up to A$4,800 per prescription. At the August 31 exchange rate, that is about US$3,440.

PBS coverage and clinical suitability answer different questions. A subsidy listing does not show that every patient with a named cancer meets the prescribing conditions or will have the same outcome.

What the PBS does

The PBS says the Australian government subsidizes medicines for most medical conditions and that medicines requiring clinical supervision are generally supplied through specialized services, usually hospitals. The scheme began in 1948 and forms part of Australia's National Medicines Policy.

The online PBS Schedule lists subsidized medicines, their prescribing conditions and what patients can expect to pay, and it is updated monthly. A listing therefore creates an Australian government payment pathway with defined conditions rather than an unrestricted entitlement based on a cancer name alone.

The August 30 announcement says clinicians will be able to prescribe pembrolizumab for the additional cancers but does not reproduce the full restriction wording. APPI News could not find final item-level restrictions for all three new indications or a cancer-by-cancer split of the 700-person projection in the material reviewed on August 31.

What patients may pay

For 2026, the PBS sets a maximum pharmacy charge of A$25 for general patients and A$7.70 for holders of specified Australian government cards that qualify them for reduced fees. Special patient contributions, brand premiums and therapeutic group premiums can be added. The first base amount is about US$18 and the second about US$5.50 at the August 31 reference rate.

Those maximum contributions are not the medicine's total cost to the Australian government, and they do not establish whether a prescription meets a listing restriction. Actual patient charges can differ when permitted premiums or special contributions apply.

The Reserve Bank of Australia reported an AUD/USD reference rate of 0.7166 on August 31, 2026, meaning A$1 equaled US$0.7166. All US dollar figures in this report use that rate and are rounded; Australian bills remain denominated in Australian dollars.

The first test is uptake after September 1

The estimates of 700 and more than 490 beneficiaries come from the Australian government's pre-launch announcement. They are forecasts, not counts of prescriptions filled or patients treated under the expanded listings.

The first measurable question is how many eligible patients use each listing after it takes effect. A breakdown by cancer type, the detailed PBS restrictions and later dispensing data will be needed to compare actual use with the headline forecast. Availability, reimbursement and regulatory status remain country-specific.